Refine by
Diabetes And Obesity Articles & Analysis: Older
44 news found
We are delighted to welcome Roczen to the community of healthcare organisations leveraging Vantage Software! We look forward to working together and helping them deliver exceptional care and support to those living with chronic conditions. Book a Free Demo ...
“Peripheral CB1 blockade has the potential to address the significant unmet medical need in DKD as well as other complications of diabetes and obesity.” “We’re excited about the progress of our INV-202 program that represents a novel, orally administered option for treating metabolic conditions,” said François Ravenelle, PhD, ...
Inversago believes that peripheral CB1 blockade, either alone or in combination with other therapies, represents an opportunity to address the significant unmet medical need of DKD. As obesity, diabetes and their complications continue to affect more people around the world, the need for new therapies will only continue to grow. ...
“This collaboration brings together two leading, diverse technological platforms and teams for the discovery of novel consumer products that may have therapeutic benefits for type 2 diabetes and obesity,” said Jay Galeota, president and CEO, Kallyope. ...
The data was presented by Robert Ryder, M.D. of City Hospital, Birmingham, U.K. at the 82nd Annual Scientific Sessions of the American Diabetes Association (ADA) in New Orleans on June 6, 2022. Both studies demonstrate the safety and efficacy profile that EndoBarrier provides patients diagnosed with type 2 diabetes and/or obesity. ...
Initial results show the duodenal jejunal bypass liner (DJBL) technology met overall glycemic control efficacy and SAE related device removal safety endpoints Findings Presented at DDW 2022 BOSTON – June 15, 2022 – GI Dynamics, a medical device company that is developing the EndoBarrier® System for patients diagnosed with type 2 diabetes and ...
Orlistat is a drug designed to treat obesity. The main function of Orlistat is to prevent the absorption of fat from the diet in humans. ...
” Over the past 13 months, Kallyope has advanced four compounds into the clinic in its two lead programs in Type 2 diabetes, obesity, and diseases of the gastrointestinal barrier. With the new funding, Kallyope will continue to move these trials forward, as well as accelerate progress on more than 20 programs and molecules in the pipeline and further ...
REVITA-1 was an open-label cohort study evaluating Revita® in patients with type 2 diabetes on oral anti-diabetic agents but not yet on insulin This is the first publication showing two-year durability of improvements in blood glucose, weight, and broader metabolic parameters with no device- or procedure-related adverse events in long-term follow-up after ...
BOSTON & HYDERABAD, India--( )-- GI Dynamics Inc., a medical device company that isBUSINESS WIRE developing the EndoBarrier® System for patients diagnosed with type 2 diabetes and obesity, is pleased to announce that it has received regulatory approval to begin enrollment in the I-STEP clinical trial in India. I-STEP is a multi-center, randomized, ...
Neurovalens, a global leader of neuro-technology products, is embarking on the development of a device for the treatment of obesity with £1m support from Invest NI. The technology is based on the neuro stimulation of specific areas of the brain responsible for influencing appetite and cravings. The company specialises in combining neuroscience and technology to tackle ...
During the quarter, we expanded our insulins access program to address the needs of young people with Type 1 diabetes in India in collaboration with the Research Society for the Study of Diabetes in India (RSSDI). ...
ByBiocon
Scientists have found that the dysbiosis of gut microbiota is linked to malnutrition, obesity, diabetes, and various other diseases. Researchers who worked on a joint project among Columbia University Medical Center, Albert Einstein College of Medicine, and St John's University sought to elucidate the mechanisms by which maternal consumption of a high-fat diet ...
"Through this collaboration, we will have the opportunity to expand treatment options available to patients suffering from metabolic disorders," said Ruth Gimeno, Ph.D., vice president, diabetes research and clinical investigation at Lilly. "Regor's technology will also allow Lilly to further accelerate innovation and deliver breakthrough therapies in obesity and ...
“Fatty liver disease is a growing global epidemic affecting more than one billion people and is commonly associated with diabetes and obesity. This disease causes permanent liver damage and mortality,” states Geyer. ...
The collaboration between Novo Nordisk and Dicerna encompassed the exploration of more than 30 liver cell targets with the potential to deliver multiple clinical candidates for disorders including chronic liver disease, non-alcoholic steatohepatitis (NASH), type 2 diabetes, obesity and rare diseases. Novo Nordisk expects to initiate clinical development of the ...
Attending physicians are invited to visit the VelacurTM booth, or register for an in-person private demo and KOL presentation to learn more about this important topic: October 24/25: Private VelacurTM Demo October 24: Reception & Keynote: “Owning NAFLD: A Win-Win for Patients & Providers” October 25: Roundtable Breakfast: “Leveraging Trends to Grow Your GI ...
The health of your brain and your heart are also connected, which means managing cardiovascular risk factors like diabetes, obesity and high blood pressure can also reduce the risk of cognitive decline. ...
In these roles, he oversaw many drug discovery and development projects targeting major global aging-related health issues, including obesity, diabetes, and heart disease. In addition to serving on the board of Deep Genomics Inc., Thomas served on the board of miRagen Therapeutics Inc. from 2009 to 2020, and is a member of several scientific and strategic ...
“I am excited and honored to join the talented team at GI Dynamics. Type 2 diabetes and associated comorbidities, including obesity, impact almost 500 million people around the globe. ...